It is quite evident that dyslipidemia and hypertension frequently coexist. There is increasing recognition of a mutually facilitative interaction between dyslipidemia and RAS activation in the development of atherosclerosis. Both share many of the same properties in terms of activation of pro-inflammatory, pro-oxidant, and pro-atherosclerosis pathways. It is no wonder that the concurrent therapy of dyslipidemia with statins enhances the effects of RAS inhibitors. Although the effects of statins on regulation of determinants of vascular stiffness are not well defined, it is quite likely that these regulatory pathways will be influenced by dyslipidemia therapy, especially statins.
1 Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK: Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999;145:33-43.
2 McEwen JE, Zimniak P, Mehta JL, Reis RJ: Molecular pathology of aging and its implications for senescent coronary atherosclerosis. Curr Opin Cardiol 2005;20:399-406.
4 West of Scotland Coronary Prevention Study (WOSCOPS): Influence of pravastatin and plasma lipids on clinical events in the WOSCOPS. Circulation 1998;97:1440-1445.
5 Mehta JL, Li DY, Chen HJ, Joseph J, Romeo F: Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 2001;289:857-861.
6 Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719.
7 Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M: Statin-sensitive dysregu-lated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.
8 Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Guttierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949.
9 Holstein SA, Wohlford-Lenane CL, Hohl RJ: Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem 2002;277:10678-10682.
10 Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cotten S, Takada Y, Hommel U: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-692.
11 Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T, Kita T: Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 1998;83:322-327.
12 Mehta JL, Li DY: Identification, regulation and function of LOX-1, a novel receptor for ox-LDL. J Am Coll Cardiol 2002;39:1429-1435.
13 Aoyama T, Chen M, Fujiwara H, Masaki T, Sawamura T: LOX-1 mediates lysophosphatidylcho-line-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett 2000;467:217-220.
14 Li DY, Chen HJ, Mehta JL: Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 2001;52:130-135.
15 Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL: LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003;107:612-617.
16 Cola C, Almeida M, Li D, Romeo F, Mehta JL: Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem Biophys Res Commun 2004;320:424-427.
17 Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D: Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000;96: 4212-4215.
18 Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U: Statins increase throm-bomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor-a-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 2003;14:575-585.
19 Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B: Simvastatin prevents angiotensin II-in-duced cardiac alteration and oxidative stress. Hypertension 2002;40:142-147.
20 Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23:729-736.
21 Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boc-cuzzi SJ, Cedarholm JC, Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
22 Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
23 Li DY, Chen HJ, Romeo F, Sawamura T, Saldeen T, Mehta JL: Statins modulate ox-LDL-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Car-diovasc Pharmacol Ther 2002;302:601-605.
24 Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935.
25 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009.
26 Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-484.
27 Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Wata-nabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-999.
28 Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G: Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-985.
29 Maeda T, Matsunuma A, Kawane T, Horiuchi N: Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001;280:874-877.
30 Keidar S, Heinrich R, Kaplan M, Aviram M: Oxidative stress increases the expression of the an-giotensin-II receptor type 1 in mouse peritoneal macrophages. J Renin Angiotensin Aldosterone Syst 2002;3:24-30.
31 Singh BK, Sinha AK, Mehta JL: Statins in the primary prevention of atherosclerosis-related events; in Mehta JL (ed): Statins: Understanding Clinical Use. Philadelphia, Saunders 2004.
32 Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL: Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999;84:1043-1049.
34 Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, Pirrelli A: Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33:719-725.
35 Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M: Statin-sensitive dysregu-lated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.
36 Vidal F, Colome C, Martinez-Gonzalez J, Badimon L: Atherogenic concentrations of native low-density lipoproteins down-regulate nitric oxide synthase mRNA and protein levels in endothe-lial cells. Eur J Biochem 1998;252:378-384.
37 Kotchen TA, Talwalkar RT: Increased enzymatic activity of renin and hyperlipidemia. Am J Physiol 1981;240:E60-E64.
38 O'Callaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howes LG, Louis WJ: Short-term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press 1994;3:404-406.
39 Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA: Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercho-lesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-1499.
40 Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E: Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35:549-555.
41 Schmalfuss CM, Chen LY, Bott JN, Staples ED, Mehta JL: Superoxide anion generation, superoxide dismutase activity, and nitric oxide release in human internal mammary artery and saphenous vein segments. J Cardiovasc Pharmacol Ther 1999;4:249-257.
42 Cooke JP: NO and angiogenesis. Atheroscler Suppl 2003;4:53-60.
43 Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, Haller H: Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation 2001;104:576-581.
44 Patel R, Nagueh SF, Tsybouleva N, et al: Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-324.
45 Reddy R, Chahoud G, Mehta JL: Modulation of cardiovascular remodeling with statins: fact or fiction? Curr Vasc Pharmacol 2005;3:69-79.
46 Daugherty A, Cassis L: Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann NY Acad Sci 1999;892:108-118.
47 Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T: Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005;19:103-109.
48 Raison J, Rudnichi A, Safar ME: Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002;16: 705-710.
49 Abetel G, Poget PN, Bonnabry JP: Hypotensive effect of an inhibitor of cholesterol synthesis (flu-vastatin). A pilot study. Schweiz Med Wochenschr 1998;128:272-277.
50 Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S, Pahor M: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-1286.
51 Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997;20:1891-1895.
52 Kontopoulos AG, Athyros VG, Pehlivanidis AN, Demitriadis DS, Papageorgiou AA, Boudoulas H: Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003;19:22-27.
53 Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, Kingwell BA: Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002;39:1020-1025.
Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences 4301 W. Markham St., Slot 532 Little Rock, AR 72205 (USA)
Tel. +1 501 296 1401, Fax +1 501 686 6180, E-Mail [email protected]
Was this article helpful?